Consolidation with allo-HSCT can benefit these patients in mitigating the adverse effect of SRSF2 mutations, demonstrated by a 2-year OS of 77% in SRSF2-mutated AML patients after undergoing transplant; however, it should be noted that the continued detection of SRSF2 mutations at HSCT (after induction of remission and before HSCT) does not seem to affect outcomes, and therefore may not be helpful as a predictive biomarker for treatment decisions [171]. Here, SRSF2 is linked to acute myeloid leukemia.